Search Result

Results for "

Integrin inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (115) Akt (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (19) Autophagy (7) Bcl-2 Family (1) Biochemical Assay Reagents (2) Btk (1) C-type Lectin-like Receptors (CTLRs) (1) Caspase (2) CD22 (1) Complement System (1) DNA Methyltransferase (1) Drug Intermediate (1) EGFR (1) Elastase (1) Endogenous Metabolite (1) Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (1) ERK (1) Factor Xa (1) FAK (6) Glutaminase (1) Glycoprotein VI (1) HSP (1) IKK (1) Interleukin Related (3) Isotope-Labeled Compounds (3) MDM-2/p53 (2) MMP (2) Molecular Glues (1) mTOR (2) NF-κB (2) NOD-like Receptor (NLR) (2) Orthopoxvirus (1) p38 MAPK (2) PD-1/PD-L1 (2) PI3K (3) Potassium Channel (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) Ser/Thr Kinase (1) Sialyltransferase (2) Src (7) STAT (3) Syk (1) TGF-beta/Smad (1) TGF-β Receptor (3) TNF Receptor (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (70) Cardiovascular Disease (29) Endocrinology (1) Infection (6) Inflammation/Immunology (49) Metabolic Disease (8) Neurological Disease (4)

By Targets:

Integrin (115)

Akt (2)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (19)

Autophagy (7)

Bcl-2 Family (1)

Biochemical Assay Reagents (2)

Btk (1)

C-type Lectin-like Receptors (CTLRs) (1)

Caspase (2)

CD22 (1)

Complement System (1)

DNA Methyltransferase (1)

Drug Intermediate (1)

EGFR (1)

Elastase (1)

Endogenous Metabolite (1)

Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (1)

ERK (1)

Factor Xa (1)

FAK (6)

Glutaminase (1)

Glycoprotein VI (1)

HSP (1)

IKK (1)

Interleukin Related (3)

Isotope-Labeled Compounds (3)

MDM-2/p53 (2)

MMP (2)

Molecular Glues (1)

mTOR (2)

NF-κB (2)

NOD-like Receptor (NLR) (2)

Orthopoxvirus (1)

p38 MAPK (2)

PD-1/PD-L1 (2)

PI3K (3)

Potassium Channel (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (4)

Ser/Thr Kinase (1)

Sialyltransferase (2)

Src (7)

STAT (3)

Syk (1)

TGF-beta/Smad (1)

TGF-β Receptor (3)

TNF Receptor (1)

VEGFR (1)

Wnt (1)

By Research Areas:

Cancer (70)

Cardiovascular Disease (29)

Endocrinology (1)

Infection (6)

Inflammation/Immunology (49)

Metabolic Disease (8)

Neurological Disease (4)

139

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Integrin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P4896

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro	Integrin	Cancer
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an *integrin* inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .

HY-W008201

tert-Butyl 3-formylpyrrolidine-1-carboxylate	Drug Intermediate	Inflammation/Immunology
tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .

HY-100506

GLPG0187 15+ Cited Publications	Integrin	Cancer
GLPG0187 is a broad spectrum *integrin* receptor antagonist with antitumor activity; inhibits α_vβ₁-integrin with an IC₅₀ of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .

HY-70073

Zaurategrast 3 Publications Verification CT7758	Integrin	Inflammation/Immunology
Zaurategrast (CT7758) is a potent and oral-effective *α₄-integrin* inhibitor .

HY-P0290A

GRGDSP TFA 5 Publications Verification	Integrin	Cancer
GRGDSP (TFA) is an *integrin* inhibitor.

HY-153807

*αvβ6 integrin* inhibitor 2**	Integrin	Inflammation/Immunology
αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC₅₀ of 96.5 nM (WO2020081154A1, example 19) .

HY-161730

αvβ1 integrin-IN-3	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .

HY-P10417

RTDLDSLRTYTL	Integrin	Others Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-177318

αLβ2 integrin-IN-1	Integrin	Inflammation/Immunology
αLβ2 integrin-IN-1 (example 1) is an αLβ2 integrin mediated cell adhesion inhibitor that can be used for the study of αLβ2 integrin mediated inflammatory conditions .

HY-P990203

Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) 1 Publications Verification	Integrin	Inflammation/Immunology
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis .

HY-156521

αvβ1 integrin-IN-2	Integrin	Others
αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of integrins ανβ1 and α5β1 with IC₅₀s of 0.9 nM，and 33 nM，respectively. αvβ1 integrin-IN-2 also inhibits other integrins with ，，IC₅₀s of 380 nM (ανβ3)，280 nM (ανβ5)，230 nM (ανβ6)，87 nM (ανβ8)，respectively，in SPRA assay .

HY-P0290

GRGDSP 5 Publications Verification	Integrin	Cancer
GRGDSP, a synthetic linear RGD peptide, is an *integrin* inhibitor.

HY-100445

αvβ1 integrin-IN-1 5 Publications Verification	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

HY-100445A

αvβ1 integrin-IN-1 TFA 5 Publications Verification	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

HY-107147

CLT-28643	Integrin	Others
CLT-28643 is an integrin α5β1 inhibitor. CLT-28643 can inhibit the high expression of integrin α5β1 in the bleb at early time-points after surgery and promote wound healing process .

HY-130119

Integrin-IN-2	Integrin	Cancer
Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC₅₀ values of 7.8, 8.4, 8.4 and 7.4, respectively .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-100563

Cyclo(RGDyK) trifluoroacetate 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) trifluoroacetate is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.

HY-100563A

Cyclo(RGDyK) 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.

HY-P0023

Cyclo(-RGDfK) 20+ Cited Publications	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P0023A

Cyclo(-RGDfK) TFA 20+ Cited Publications	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-12290

Arg-Gly-Asp-Ser 5+ Cited Publications RGDS peptide; Fibronectin tetrapeptide	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

HY-150124A

K34c hydrochloride	Integrin Apoptosis	Cancer
K34c hydrochloride is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c hydrochloride reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c hydrochloride can be used in glioblastoma research .

HY-150124

K34c	Integrin Apoptosis	Cancer
K34c is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c can be used in glioblastoma research .

HY-159179

α4 integrin receptor antagonist 3	Integrin	Inflammation/Immunology
α4 integrin receptor antagonist 3 (Compound 11) is an orally active α₄integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between α₄β₁/VCAM-1 and α₄β₇/MAdCAM-1, with IC₅₀ values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model .

HY-P10038

mP6 Myr-FEEERA-OH	Integrin	Infection
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .

HY-12290A

Arg-Gly-Asp-Ser TFA RGDS peptide TFA; Fibronectin tetrapeptide TFA	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .

HY-P10038A

mP6 TFA Myr-FEEERA-OH TFA	Integrin	Infection
mP6 (Myr-FEEERA-OH) TFA is a myristoylated peptide. mP6 TFA inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 TFA can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .

HY-P10984

FNIII14	Integrin	Metabolic Disease Inflammation/Immunology Cancer
FNIII14 is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule. FNIII14 is capable of inhibiting cell adhesion to the extracellular matrix (ECM). FNIII14 induces a conformational change in *β1-integrin* from the active to the inactive form, and blocks integrin-mediated signaling. FNIII14 has anti-fibrotic, anti-cancer effect. FNIII14 can be used for research of metabolic diseases, organ fibrosis, and malignant tumors .

HY-139137

N-Acetyl-S-geranylgeranyl-L-cysteine AGGC	DNA Methyltransferase Integrin	Cancer
N-Acetyl-S-geranylgeranyl-L-cysteine is a Methyltransferase inhibitor. N-Acetyl-S-geranylgeranyl-L-cysteine inhibits beta 2 integrin-induced actin polymerization with an IC₅₀ of 45 nM .

HY-126039

L-739758	Integrin	Cardiovascular Disease
L-739758 is an antagonist for αIIbβ3 integrin (platelet glycoprotein IIb/IIIa). L-739758 acts as a peptidomimetic, binds to αIIbβ3 integrin by mimicking the interaction of the RGD (arginine-glycine-aspartic acid) motif, and is involved in the blood coagulation process. L-739758 inhibits platelet aggregation, and is used for thrombosis research .

HY-P5038

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) c(GRGDSP)	Integrin	Cancer
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 *integrin* ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .

HY-13535

ATN-161 5+ Cited Publications	Integrin	Cancer
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

HY-P3530

G-{d-Arg}-GDSP	Integrin	Others
G-{d-Arg}-GDSP is an RGD peptide analogue that binds to the adhesion receptor of integrins and inhibits cellular fibronectin attachment as well as osteoclast resorption .

HY-16143

Cilengitide TFA Maximum Cited Publications 62 Publications Verification EMD 121974 TFA	Integrin Autophagy	Cancer
Cilengitide is a potent and selective *integrin* inhibitor for α_vβ₃ and α_vβ₅ receptor, with IC₅₀ values of 4 nM and 79 nM, respectively.

HY-13535A

ATN-161 trifluoroacetate salt 5+ Cited Publications ATN-161 TFA salt	Integrin	Cancer
ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule-drug conjugates (SMDCs) consisting of an αvβ3 integrin binder linked to an optimized Camptothecin (HY-16560) topoisomerase I (TOP1) inhibitor payload. VIP236 exerts anticancer activity by targeting αvβ3 integrins, and it can release payload upon cleavage by neutrophil elastase in the tumor microenvironment .

HY-10306

Gantofiban	Integrin	Cardiovascular Disease
Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from foot-and-mouth disease virus and is a 20-amino-acid peptide. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-164957

SGN-B6A	Antibody-Drug Conjugates (ADCs) Integrin	Cancer
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P99333

Volociximab 2 Publications Verification M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-19767A

GSK 3008348 hydrochloride 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .

HY-12290R

Arg-Gly-Asp-Ser (Standard)	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser (Standard) is the analytical standard of Arg-Gly-Asp-Ser. This product is intended for research and analytical applications. Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

HY-14571

E7820 5 Publications Verification ER68203-00	Molecular Glues Integrin	Cancer
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC₅₀ of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity .

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

HY-120800

KUNG29	HSP	Metabolic Disease
KUNG29 is a potent and selective Grp94 inhibitor with a Kd of 0.2 μM. KUNG29 induces the degradation of integrin α2 in MDA-MB-231 cells .

Cat. No.	Product Name	Type

HY-W008201

tert-Butyl 3-formylpyrrolidine-1-carboxylate	Biochemical Assay Reagents
tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .

HY-NP132

Recombinant Humanized Type III Collagen 28.6kDa

Biochemical Assay Reagents

Recombinant Humanized Type III Collagen 28.6kDa is a type III collagen 28.6kDa. Recombinant humanized type III collagen (rhCOLIII) has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. rhCOLIII inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .

HY-NP132A

Recombinant humanized type III collagen (MW 55900)

Biochemical Assay Reagents

Recombinant humanized type III collagen (MW 55900) is a type III collagen with a molecular weight of 55900 Da. Recombinant humanized type III collagen has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. Recombinant humanized type III collagen inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .

Cat. No.	Product Name	Target	Research Area

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P4896

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro	Integrin	Cancer
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an *integrin* inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .

HY-P0290A

GRGDSP TFA 5 Publications Verification	Integrin	Cancer
GRGDSP (TFA) is an *integrin* inhibitor.

HY-P0290

GRGDSP 5 Publications Verification	Integrin	Cancer
GRGDSP, a synthetic linear RGD peptide, is an *integrin* inhibitor.

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-100563

Cyclo(RGDyK) trifluoroacetate 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) trifluoroacetate is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.

HY-100563A

Cyclo(RGDyK) 4 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.

HY-P0023

Cyclo(-RGDfK) Maximum Cited Publications 23 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P10417

RTDLDSLRTYTL	Integrin	Others Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-P0023A

Cyclo(-RGDfK) TFA Maximum Cited Publications 23 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-12290

Arg-Gly-Asp-Ser 5+ Cited Publications RGDS peptide; Fibronectin tetrapeptide	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

HY-P10038

mP6 Myr-FEEERA-OH	Integrin	Infection
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .

HY-12290A

Arg-Gly-Asp-Ser TFA RGDS peptide TFA; Fibronectin tetrapeptide TFA	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .

HY-P10038A

mP6 TFA Myr-FEEERA-OH TFA	Integrin	Infection
mP6 (Myr-FEEERA-OH) TFA is a myristoylated peptide. mP6 TFA inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 TFA can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .

HY-P10984

FNIII14	Integrin	Metabolic Disease Inflammation/Immunology Cancer
FNIII14 is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule. FNIII14 is capable of inhibiting cell adhesion to the extracellular matrix (ECM). FNIII14 induces a conformational change in *β1-integrin* from the active to the inactive form, and blocks integrin-mediated signaling. FNIII14 has anti-fibrotic, anti-cancer effect. FNIII14 can be used for research of metabolic diseases, organ fibrosis, and malignant tumors .

HY-P5038

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) c(GRGDSP)	Integrin	Cancer
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 *integrin* ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .

HY-P3530

G-{d-Arg}-GDSP	Integrin	Others
G-{d-Arg}-GDSP is an RGD peptide analogue that binds to the adhesion receptor of integrins and inhibits cellular fibronectin attachment as well as osteoclast resorption .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from foot-and-mouth disease virus and is a 20-amino-acid peptide. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-12290R

Arg-Gly-Asp-Ser (Standard)	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser (Standard) is the analytical standard of Arg-Gly-Asp-Ser. This product is intended for research and analytical applications. Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

HY-P10704

C16Y	Integrin	Cancer
C16Y is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-P11495

myr-RGT	Integrin	Cardiovascular Disease
myr-RGT is a nutmeg acylated RGT peptide. myr-RGT can be used to inhibit extracellular signaling of integrin β3. myr-RGT can be used in the research of atherosclerosis and other related conditions .

HY-125053A

Batifiban TFA	Glycoprotein VI	Cardiovascular Disease
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .

HY-P1408

Obtustatin 2 Publications Verification	Integrin	Cancer
Obtustatin is a non-RGD disintegrin of 41 residues. Obtustatin can be isolated from Vipera lebetina obtusa venom. Obtustatin is a potent and selective inhibitor of the adhesion of integrin α1β1 to collagen IV. Obtustatin inhibits angiogenesis, and can be used for research of cancer .

HY-125053

Batifiban	Integrin	Cardiovascular Disease
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .

HY-P5133

Synstatin (92-119) 1 Publications Verification SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-P1408A

Obtustatin triacetate 2 Publications Verification	Integrin	Cancer
Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 peptide (Tumstatin (74-98), human) is an endothelial cell-specific inhibitor. T7 peptide interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, PKB/Akt, and mTOR signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis .

HY-P4320

Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10)	Integrin	Cancer
Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10), a decapeptide containing a cyclic RGD active sequence, is an *Integrin* αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13 .

HY-P10323A

T7 Peptide TFA Tumstatin (74-98), human TFA	Integrin FAK mTOR Apoptosis	Cancer
T7 peptide (Tumstatin (74-98), human) TFA is an endothelial cell-specific inhibitor. T7 peptide TFA interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, PKB/Akt, and mTOR signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P1740

RGD peptide (GRGDNP) 5 Publications Verification	Integrin Apoptosis Caspase	Inflammation/Immunology
RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .

HY-P1740A

RGD peptide (GRGDNP) (TFA) 5 Publications Verification	Integrin Apoptosis	Inflammation/Immunology Cancer
RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .

HY-P10988

LVTX-8	Apoptosis MDM-2/p53 Integrin	Cancer
LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model .

HY-P2300A

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA 2 Publications Verification Cyclo(RGDfC) TFA	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) 2 Publications Verification Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-P10993

CT20p	Bcl-2 Family	Cancer
CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce α5β1 *integrin* levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer .

HY-P10934

LXY3 LXY2	Integrin	Cancer
LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P990203

Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) 1 Publications Verification	Integrin	Inflammation/Immunology
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis .

HY-P99333

Volociximab 2 Publications Verification M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-P990552A

huATN-658 MNPR-101	Integrin	Cancer
huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) .

HY-P990781

Suciraslimab SM03	CD22 NOD-like Receptor (NLR) Interleukin Related Integrin	Neurological Disease Inflammation/Immunology
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation . Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990835

Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13)	Integrin	Infection Inflammation/Immunology
Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human LFA-1α/CD11a. Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) reacts with human LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) can be used for the researches of immunology and infection, such as human immunodeficiency virus (HIV) .

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

HY-P991652

MINT1526A RG-7594	Integrin	Cancer
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research .

HY-P991254

VPI-2690B	Integrin TGF-β Receptor	Metabolic Disease
VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .

HY-P990871

Anti-CD11a/LFA-1α Antibody (R7-1)	Integrin	Inflammation/Immunology
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human CD11a/LFA-1α. Anti-CD11a/LFA-1α Antibody (R7-1) can neutralize LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. Anti-CD11a/LFA-1α Antibody (R7-1) can be used for the research of inflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113439

12-HETE 2 Publications Verification	Microorganisms Source classification	Apoptosis
12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .

HY-N0031

Plantamajoside 2 Publications Verification	Plantaginaceae Classification of Application Fields Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plantago asiatica L. Plants Inflammation/Immunology Disease Research Fields	NF-κB PI3K Akt Apoptosis Autophagy p38 MAPK Src
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

HY-136699

Excisanin A	Terpenoids Labiatae Source classification Diterpenoids Baccharis densiflora Wedd. Plants	MMP FAK Src Integrin
Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer .

HY-122552

Chrysotobibenzyl	Natural Products Orchidaceae Source classification Plants Dendrobium pulchellum Roxb. et Lindl. :Lindl.	Integrin
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394) .

HY-N0031R

Plantamajoside (Standard)	Plantaginaceae Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plantago asiatica L. Plants	Reference Standards NF-κB PI3K Apoptosis Autophagy p38 MAPK Src
Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

Cat. No.	Product Name	Chemical Structure

HY-113439S

12-HETE-d8 1 Publications Verification
12-HETE-d₈ is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .

HY-19344S2

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Integrin inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products